Stable formulations for radionuclide complexes.

JP2023552180A5Inactive Publication Date: 2024-12-04ITM SOLUCIN GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023532682
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-25
Filing Date
2021-11-24
Publication Date
2024-12-04
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Radiopharmaceuticals containing radionuclide complexes are prone to instability due to radioactive decay, leading to partial drug destruction and reduced effectiveness, which poses challenges for production, storage, and transportation, and existing formulations often require complex mixtures of antioxidants that are not well tolerated upon injection.

Method used

A pharmaceutical composition comprising a radiolabeled complex with a radionuclide and a target molecule linked to a chelating agent, stabilized by ascorbic acid and/or its salts, without gentisic acid, which acts as a stabilizer and pH adjuster, ensuring increased stability and high radiolabel yields.

Benefits of technology

The formulation achieves extended stability of radionuclide complexes for at least 96 hours, maintaining high radiochemical purity and avoiding complex mixtures, while being well tolerated upon injection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000041_0000
    Figure 00000041_0000
  • Figure 00000041_0001
    Figure 00000041_0001
  • Figure 00000042_0000
    Figure 00000042_0000
Patent Text Reader

Abstract

The present invention provides a pharmaceutical composition comprising a radiolabeled complex comprising a radionuclide and a targeting molecule linked to a chelator, and a stabilizer against radiolysis comprising ascorbic acid and / or a salt thereof, the stabilizer not comprising gentisic acid or a salt thereof. The pharmaceutical composition of the present invention provides high stability against radiolysis. The present invention also provides a process for preparing such a pharmaceutical composition.
Need to check novelty before this filing date? Find Prior Art

Description

Detailed description of the invention

[0001] The present invention relates to the field of radiopharmaceutical formulations, and more particularly to formulations that guarantee the stability of radionuclide complexes, and to methods for preparing such formulations.

[0002] Radiopharmaceuticals are drugs that contain radioisotopes (radionuclides). Radiopharmaceuticals can be used to treat a variety of conditions, including cancer, blood disorders, and hyperthyroidism. In radionuclide therapy for cancer, molecules labeled with radionuclides are used to deliver toxic levels of radiation to the diseased site. Thus, the molecules are used to "target" the diseased site, for example, specific cancer cells. Therefore, radionuclide complexes combine the specificity of cancer cell targeting with the known antitumor effects of ionizing radiation. This allows for targeting not only the primary tumor site but also its metastases. The selection of molecules to deliver radiation to the tumor is usually determined by their selectivity and affinity for tumor target structures, such as antigens or receptors. Overexpressed target structures are interesting because they allow for the delivery of radionuclide complexes after systemic administration at high concentrations to (overexpressed) target cells, even if the target structure is not selective for a particular type of cancer, while other cells (without expression or only slight expression) remain unaffected. Radionuclides are typically linked to target molecules via chelating agents. This allows them to form strong complexes with metal ions. The radioactive decay of radionuclides can cause significant damage to cancer cells by emitting high-energy electrons, positrons, or alpha particles, as well as gamma rays, at the target site.

[0003] However, radioactive decay of radionuclides occurs constantly, including during the production and storage of radionuclide complexes. The high energy released during radioactive decay can induce the cleavage of chemical bonds in radionuclide complexes, thereby potentially leading to the partial destruction of the drug due to its radioactivity. Radiolysis of the target molecule of a radionuclide complex can lead to a degradation of the specificity of the radionuclide complex, thereby potentially resulting in a decrease in its efficacy and / or an increase in undesirable side effects.

[0004] Therefore, the stability of radiopharmaceuticals is typically limited to a few hours or days. This presents various challenges regarding the manufacture, storage, and transportation of radiopharmaceuticals. Consequently, only a limited opportunity for application of radiopharmaceuticals after manufacture is available.

[0005] To mitigate this problem, antioxidants such as gentisic acid, ethanol, ascorbic acid, and methionine are typically added to radionuclide complex formulations. However, in particular, 177 For Lu-labeled peptides, such as DOTATOC (edotreotide) and DOTATATE (oxodotreotide), a complex mixture of antioxidants or a specific timing of their addition is often required to obtain the desired effect over an acceptable period. For example, Maus et al. [ 177The radiolabeling of Lu]Lu-DOTATATE and the addition of purified ascorbic acid have been reported (Stephan Maus et al., Aspects on radiolabeling of 177Lu-DOTA-TATE: After C18 purification re-addition of ascorbic acid is required to maintain radiochemical purity, International Journal of Diagnostic Imaging, 2014, Vol. 1, No. 1). U.S. Patent No. 10,756,278B2 requires a complex mixture of radiolabeled gentisic acid, ascorbic acid, and EDTA to obtain the desired stability against 95% radiolysis within 72 hours after synthesis. De Blois et al. and Breeman et al. suggest the addition of a mixture of 50 mM ascorbic acid, 10% (v / v) ethanol, and 50 mM L-methionine (Erik de Blois et al. Effectiveness of Quenchers to Reduce Radiolysis of (111)In-Or(177)Lu-labeled Methionine-Containing Regulatory Peptides. Maintaining Radiochemical Purity as Measured by HPLC. Curr Top MedChem. 2012 12(23):2677-85; Wouter A. P. Breeman; Practical Aspects of labeling DTPA- and DOTA-Peptides with 90Y, 111In, 177Lu, and 68Gafor Peptide-Receptor Scintigraphy and Peptide-Receptor Radionuclide Therapy in Preclinical and Clinical Applications, The University of New Mexico Health Sciences). Center, Vol. 16, LESSON 5: November 16, 2012). According to these reports, 177For Lu-labeled peptides, stabilizers, or second or third stabilizing components, are added only after radiolabeling in acetic acid or HEPES buffer.

[0006] In consideration of the above, the object of the present invention is to provide novel formulations for radionuclide complexes that overcome the drawbacks outlined above and ensure increased stability of the radionuclide complex over extended periods. In particular, such formulations contain as few components as possible and are well acceptable for parenteral injection. Furthermore, the antioxidants used in the formulations also function as pH adjusters / buffers (especially in a pH range acceptable for parenteral injection, such as pH 4.5-8), thus avoiding complex mixtures. Moreover, the antioxidants used in the formulations may also function as buffers for radiolabeling, resulting in high radiolabeling yields, which further avoids complex mixtures.

[0007] This objective is achieved by the subject matter described in the following specification and the attached claims.

[0008] The present invention is described in detail below, but it should be understood that the present invention is not limited to the specific methodologies, protocols, and reagents described herein, and that these may vary. Furthermore, it should be understood that the terms used herein are not intended to limit the scope of the present invention, but are limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.

[0009] The elements of the present invention are described below. These elements are listed together with specific embodiments, but it should be understood that they can be combined in any way and in any number to create additional embodiments. The various examples and preferred embodiments described should not be construed as limiting the invention to only the explicitly described embodiments. This description should be understood as supporting and encompassing embodiments that combine the explicitly described embodiments with any number of disclosed and / or preferred elements. Furthermore, any substitution and combination of all elements described in this application should be considered disclosed by this description unless the context indicates otherwise.

[0010] Throughout this specification and the following claims, unless otherwise required by context, variations such as “comprise,” “comprises,” and “comprising” are understood to mean the inclusion of specified components, integers, or steps, but not the exclusion of any other unspecified components, integers, or steps. The term “consist of” is a specific embodiment of the term “contains,” excluding any other unspecified components, integers, or steps. In the context of this invention, the term “comprise” encompasses the term “consist of.” Thus, the term “comprising” encompasses both “including” and “consisting,” for example, a composition “comprising” X may consist only of X, or it may include something additional, such as X + Y.

[0011] In the context describing the present invention (particularly in the context of the claims), the terms “a,” “an,” and “the,” as well as similar references, should be interpreted as encompassing both singular and plural, unless otherwise indicated herein or unless the context clearly contradicts this interpretation. References of value ranges herein are intended merely as a concise way of individually referring to each distinct value that falls within that range. Unless otherwise indicated herein, each individual value is incorporated herein as if it were individually listed herein. No language herein should be interpreted as indicating an unclaimed element essential to the practice of the present invention.

[0012] The term "substantially" does not exclude "completely"; for example, a composition that "substantially does not contain" Y does not necessarily have to contain Y completely. The word "substantially" may be excluded from the definition of this invention as needed.

[0013] When the term "about" is added to a numerical value x, it means x ± 20%, preferably x ± 10%, more preferably x ± 5%, even more preferably x ± 2%, and even more preferably x ± 1%.

[0014] [Pharmaceutical composition] In a first embodiment, the present invention provides a pharmaceutical composition comprising: (a)(i) radioactively labeled complexes comprising a radionuclide and (ii) a target molecule linked to a chelating agent; and, (b) Stabilizers for radiolysis, including ascorbic acid and / or its salts; It contains gentisic acid or its salts.

[0015] The inventors have surprisingly found that formulations of such radionuclide complexes reliably increase the stability of the radionuclide complex over an extended period, particularly over at least 96 hours. Interestingly, the extended stability / storage life can be achieved with formulations containing fewer components and therefore less complexity compared to conventional formulations for radionuclide complexes. In particular, the antioxidants used in the formulations can also act as pH adjusters / buffers (especially within a pH range acceptable for parenteral injection, such as pH 4.5-8), thus avoiding complex mixtures. Furthermore, the antioxidants used in the formulations can also function as buffers for radiolabeling, resulting in a high radiolabeling yield, which further avoids complex mixtures. Nevertheless, the compositions are well acceptable, for example, for parenteral injection.

[0016] [Radiolabeled complex] A radiolabeled complex comprising (i) a radionuclide and (ii) a target molecule linked to a chelating agent is typically formed by (i) the radionuclide and (ii) the target molecule linked to the chelating agent, for example, in step (i) of the method described below herein. Various radiolabeled complexes are known in the art. Particularly preferred examples of radiolabeled complexes are described in WO2018 / 215627A1, which is incorporated herein by reference. Furthermore, examples of commercially available radiolabeled complexes include, [ 177 Lu]Lu-DOTATATE (Lutathera (registered trademark)), [ 131 I]I-mIBG, 153 Sm-EDTMP (Quadramet (registered trademark)), 89 Sr chloride, 90 Examples include Y-filled microspheres (TheraSphere® or SIR-Sphere®) and yttrium-90 ibritumomabthiouxetane (Zevalin®).

[0017] [Radioactive nuclides] Various radionuclides (radioisotopes) are known to be useful in the field of radionuclide therapy. In particular, the term "radionuclide" (or "radioisotope") refers to an isotope of natural or artificial origin having an unstable neutron-to-proton ratio that decays by the emission of corpuscles (i.e., protons (alpha rays) or electrons (beta rays) or electromagnetic rays (gamma rays)). In other words, radioactive decay occurs in radionuclides. The radionuclides may preferably be useful for cancer imaging or treatment. Non-limiting examples of suitable radionuclides include 94 Tc, 99m Tc, 90 In, 111 In, 67 Ga, 68 Ga, 86 Y, 90 Y, 177 Lu, 151 Tb, 186 Re, 188 Re, 64 Cu, 67 Cu, 55 Co, 57 Co, 43 Sc, 44 Sc, 47 Sc, 225 Ac, 213 Bi, 212 Bi, 212 Pb, 227 Th, 153 Sm, 166 Ho, 152 Gd, 153 Gd, 157 Gd, and 166 Dy are included. Thus, the radionuclide may be any of the examples described above. The selection of a suitable radionuclide may depend inter alia on the chemical structure and the chelating ability of the chelating agent, as well as the intended application (e.g., diagnostic vs. therapeutic) of the resulting (complexed) complex. For example, 90 Y, 131 I, 161 Tb and 177 Lu and other beta emitters may be used for systemic radionuclide therapy. For example, DOTA as a chelating agent, as a radionuclide, 68 Ga, 43 Sc, 44 Sc,47 Sc, 177 Lu, 161 Tb, 225 Ac, 213 Bi, 212 Bi, or 212 This could make the use of Pb more advantageous.

[0018] Preferably, the radioactive nuclide is 44 It may be Sc. More preferably, the radionuclide is 64 It may be Cu. In some preferred embodiments, the radionuclide is 68 It could be so.

[0019] More preferably, the radioactive nuclide is 177 It is Lu (Lutetium-177).

[0020] In some embodiments, radionuclides, particularly 177 Lu is present in the pharmaceutical composition at a concentration that provides a volume radioactivity of 0.25 to 0.6 GBq / ml, preferably 0.3 to 0.55 GBq / ml, more preferably 0.35 to 0.5 GBq / ml, and even more preferably 0.4 to 0.45 GBq / ml, for example, about 0.42 GBq / ml.

[0021] [Chelating agent] In radiolabeled complexes, radioactive nuclide metal ions typically form non-covalent bonds with the functional groups of the chelating agent, such as amines or carboxylic acids. Typically, the chelating agent has at least two such complexing functional groups and can form a chelate complex.

[0022] As used herein, the term “chelating agent” (also called “chelator”) refers to a polydentate (multiple bond) ligand that can form (“coordinate”) two or more separate coordinate bonds with a central (metal) ion, particularly a radionuclide metal ion. Specifically, such molecules or molecules that share one electron pair may also be called “Lewis bases.” The central (metal) ion is typically coordinated to the chelating agent by two or more electron pairs. The terms “bidentate chelating agent,” “tricate chelating agent,” and “tetradentate chelating agent” are known in the art and refer to chelating agents having 2, 3, and 4 electron pairs, respectively, and are readily available for the simultaneous donation of electrons to the metal ion coordinated by the chelating agent. Typically, the electron pairs of a chelating agent form a coordinate bond with a single central (metal) ion, but in certain cases, the chelating agent can form coordinate bonds with two or more metal ions, and a variety of bonding modes are possible.

[0023] The terms "coordinating" and "coordination" refer to an interaction in which one multi-electron pair donor forms a coordinate bond ("coordination") with one central (metal) ion, that is, an interaction in which two or more lone pairs of electrons are shared.

[0024] The chelator or chelating agent is preferably a macrocyclic bifunctional chelating agent having a metal chelating group at one end and a reactive functional group at the other end, which can bind to other parts, such as peptides. Preferably, the chelator may be selected such that it forms a bisquare pyramidal structure for complexing radionuclides. In another embodiment, the chelator does not form a planar or square planar complex.

[0025] The chelating agent can be selected based on its ability to coordinate the desired central (metal) ion, typically the radionuclides described herein. Preferably, the chelating agent is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), N,N''-bis[2-hydroxy-5-(carboxyethyl)-benzyl]ethylenediamine-N,N''-diacetic acid (HBED-CC), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid (NODAGA), 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl)pentanedioic acid (DOTAGA), 1,4,7-triazacyclononanephosphinic acid (TRAP), 1,4,7-triazacidonanane-1-[methyl( Selected from 2-carboxyethyl)-phosphinic acid]-4,7-bis[methyl(2-hydroxymethyl)phosphinic acid](NOPO), 3,6,9,15-tetraazabicyclo[9,3,1]pentadeca-1(15), 11,13-triene-3,6,9-triacetic acid (PCTA), N'-{5-[acetyl(hydroxy)amino]pentyl}N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide (DFO), ethylenediaminetetraacetic acid (EDTA), nitrilotriacetic acid (NTA), 1,4,7,10-tetraazabicyclododecane-1,4,7-triacetic acid (DO3A), and diethylene-triaminepentaacetic acid (DTPA).

[0026] Therefore, chelating agents can be characterized by one of the following equations (1a) to (1kk):

[0027] [ka] JPEG2023552180000002.jpg178169 JPEG2023552180000003.jpg201169 JPEG2023552180000004.jpg89169 More preferably, the chelating agent may be DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) characterized by formula (1a), NODAGA (2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)-pentanedioic acid) characterized by formula (1c), or derivatives thereof.

[0028] Other preferred chelating agents in the context of the present invention include N,N''-bis[2-hydroxy-5-(carboxyethyl]benzyl]ethylenediamine-N,N''-diacetic acid (HBED-CC), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl)pentanedioic acid (DOTAGA), 1,4,7-triazacyclononanephosphinic acid (TRAP), and 1,4,7-triazaside-nonane-1-[methyl(2-carboxy It contains ethyl)-phosphinic acid]-4,7-bis-[methyl(2-hydroxymethyl)-phosphinic acid] (NOPO), 3,6,9,15-tetra-azabicyclo[9,3,1]-pentadeca-1(15), 11,13-triene-3,6,9-triacetic acid (PCTA), N'-{5-[acetyl(hydroxy)amino]-pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide (DFO), and diethylene-triaminepentaacetic acid (DTPA).

[0029] Particularly preferred is DOTA as the chelating agent. Advantageously, DOTA is used for diagnostic purposes (e.g., 68 Ga) and therapeutic (e.g., 90 Y or 177Lu) effectively forms complexes with radionuclides, thus enabling the use of the same complex (target molecule linked to the chelating agent) for both imaging and therapeutic purposes, i.e., as a theragnostic drug. DO3AP (may be characterized by formula (1hh)), DO3AP PrA (Can be characterized by formula (4ii)), or DO3AP ABn Scandium radionuclides, including those that can be characterized by formula (4jj) ( 43 Sc, 44 Sc, 47 DOTA derivatives that can complex with Sc) may also be preferred, as described by Kerdjoudj et al. (Dalton Trans, 2016, 45, 1398-1409).

[0030] A chelating agent, such as DOTA, can form a complex with any known radionuclide (in particular, the radionuclides mentioned above) as a central (metal) ion. Selecting an appropriate combination of complex and radionuclide is within the scope of the art and knowledge of those skilled in the art. In some embodiments, the chelating agent may be DOTA, and the radionuclide may be 68 It may be Ga. In other embodiments, the chelating agent may be DOTA, and the radionuclide may be 44 It may also be Sc. In a further embodiment, the chelating agent may be DOTA, and the radionuclide is 64 It may be Cu. In other embodiments, the chelating agent may be NODAGA, and the radionuclide may be 64 It may also be Cu. Particularly preferred is DOTA as the chelating agent, and the radionuclide is 177 It is Lu.

[0031] [Target molecule] As used herein, the term “target molecule” (also called “target portion”) refers to a molecule that can (specifically) bind to a “target,” such as a target cell (e.g., a cancer cell). In particular, the “target” may be a molecule located on the cell surface of a target cell (e.g., a cancer cell). Such a surface molecule to which the target molecule binds may be, for example, a receptor located on the cell surface. In particular, the surface molecule is specific to the target cell (e.g., a cell “marker”) or is overexpressed by the target cell. The target molecule may, for example, bind to a disease (e.g., cancer) marker (expressed / located on the surface of cells involved in the disease, e.g., cancer cells). Thereafter, the target molecule can specifically deliver a radionuclide to cells involved in the disease, e.g., cancer cells. Thus, the target molecule is usually selected depending on the disease being treated or diagnosed. In the context of a disease, e.g., cancer, cells targeted by a radiolabeled complex, e.g., cancer cells, usually express (or overexpress) specific molecules that can function as “targets” (surface molecules). The target molecule is typically selected to bind to the “target” (a surface molecule, and therefore to a target cell, such as a cancer cell). The binding of the target molecule to the surface molecule may be reversible or irreversible. In some embodiments, the target molecule is a peptide or polypeptide, or a modified peptide or polypeptide.

[0032] Various surface molecules to which target molecules can appropriately bind are known in the art. Below, examples of receptors and cell surface molecules present on tumor cells that can serve as target structures for target molecules are described in detail. However, target structures are not limited to the receptors and cell surface molecules described below. Further receptors and cell surface molecules present on cancer or other diseased cells are intended as target structures for target molecules. Furthermore, further target molecules targeting receptors and cell surface molecules present on cancer or other diseased cells are intended.

[0033] Particularly suitable surface molecules are PSMA and somatostatin receptors. Therefore, the target molecule can preferably bind to PSMA or somatostatin receptors.

[0034] [PSMA target compound] Human prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), folate hydrolase 1, folyl poly-γ-glutamate carboxypeptidase (FGCP), and N-acetylated-α-linked acid dipeptidase I (NAALADase I), is a type II transmembrane zinc metallopeptidase most highly expressed in the nervous system, prostate, kidney, and small intestine. PSMA is considered a tumor marker in prostate cancer. As used herein, the term “human prostate-specific membrane antigen,” or “PSMA,” preferably refers to the protein encoded by the human FOLH1 gene. More preferably, the term refers to the protein characterized under UniProt Acc. No. Q04609 (entry version 186, last modified May 10, 2017) or its functional variants, isoforms, fragments, or derivatives (post-translational or otherwise modified).

[0035] PSMA-binding target molecules are generally conjugates that can selectively (and possibly irreversibly) bind to (human) prostate-specific membrane antigens (as described, e.g., Chang Rev Urol, 2004;6(Suppl 10):S13-S18). PSMA-binding target molecules are preferably selected by their ability to confer selective affinity to PSMA. Preferred PSMA-binding moieties are described in WO2013 / 022797A1, WO2015 / 055318A1, and EP2862857A1, the whole of which is incorporated herein by reference.

[0036] Therefore, the PSMA target molecule is preferably represented by general formula (2):

[0037] [ka] Here, X is selected from O, N, S, or P. R3 and R 4 and R 5 are each independently selected from -COH, -CO2H, -SO2H, -SO3H, -SO4H, -PO2H, -PO3H, -PO4H2, -C(O)-(C1-C 10 )alkyl, -C(O)-O(C1-C 10 )alkyl, -C(O)-NHR 8 or -C(O)-NR 8 R 9 where R 8 and R 9 are each independently H, a bond, (C1-C 10 )alkylene, F, Cl, Br, I, C(O), C(S), -C(S)-NH-benzyl, -C(O)-NH-benzyl, -C(O)-(C1-C 10 )alkylene, -(CH2) p -NH, -(CH2) p -(C1-C 10 )alkylene, -(CH2) p -NH-C(O)-(CH2) q , -(CH r CH2) t -NH-C(O)-(CH2) p , -(CH2) p -CO-COH, -(CH2) p -CO-CO2H, -(CH2) p -C(O)NH-C[(CH2) q -COH]3, -C[(CH2) p -COH]3, -(CH2) p -C(O)NH-C[(CH2) q -CO2H]3, -C[(CH2) p -CO2H]3, or -(CH2) p -(C5-C 14 )heteroaryl, and b, p, q, r, t are each independently integers selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0038] In a preferred PSMA target molecule, b may be an integer selected from 1, 2, 3, 4 or 5, R 3 , R4 and R 5 Each of these can be CO2H, and X can be O.

[0039] Preferred examples of small molecule PSMA targeting agents capable of binding to the extracellular domain of PSMA include, but are not limited to, several urea-based peptide-mimicking PSMA inhibitors, such as radiolabeled N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-S-[11C]methyl-l-cysteine ​​(DCFBC), MIP-1095 (Hillier et al. Cancer Res. September 1, 2009; 69(17):6932-40), disclosed in Bouchelouche et al., Discov Med. 2010 Jan; 9(44):55-61, and the DOTA-conjugated PSMA inhibitor PSMA-617 (JNM 2015, 56 914-920 and EP2862857A1) developed by Benesova et al.

[0040] Urea-based PSMA ligands typically consist of three components: a binding motif (Glu-urea-Lys), a linker, and a radiolabeled support (a chelating molecule for radiolabeling or a prosthetic group for fluorinating). Examples of the most commonly used low-molecular-weight PSMA ligands include: 123 I-MIP-1072 and 123 I-MIP-1095 (Barrett JA et al. Med.2015;56:1697-1705) and PSMA-I&T (Weineisen M et al, J Nucl Med.2015;56:1169-1176), PSMA-I&S (Robu S et al, J Nucl Med.2017;58:235-242). moreover, 18 F-labeled small molecule urea derivative, 18F-DCFPyL (Chen Y et al, Clin Cancer Res. 2011;17:7645-7653) and 18 F-PSMA-1007 (Giesel FL et al, Eur J Nucl Med Molecular Imaging. 2017; 44:678-688) is one example.

[0041] Recently, Kelly et al. (Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer J Nucl Med. 2017 September;58(9):1442-1449 doi:10.2967 / jnumed.116.188722) evaluated drugs that show affinity for both PSMA and human serum albumin (HSA). The ligand developed by Kelly et al. contains a p-(iodophenyl)butyrate entity for HSA binding and a urea-based PSMA binding entity. In the compound developed by Kelly et al., radiotherapeutic iodine ( 131 I) is covalently bonded to the HSA binding site, which then directly binds to the PSMA binding entity via the hydrocarbyl chain.

[0042] Another example is one having an albumin conjugate. 177 It is a Lu-labeled phosphoramidate-based PSMA inhibitor (Choy et al. Theranostics 2017;7(7):1928-1939). 177 A DOTA chelating agent that complexes Lu radionuclides was ether-conjugated to the irreversible PSMA inhibitor CTT1298 (Publication EP2970345A1).

[0043] Therefore, the target molecule in the radiolabeled complex is preferably a PSMA target molecule, which can be bound to the chelating agent molecule defined above, and to the radionuclide defined above, for example, 177 It can be complexed with Lu.

[0044] The target molecule and the chelating agent typically form a conjugate or molecule (suitable for radiolabeling) together. Various such conjugates / molecules are known in the art. A preferred conjugate comprising a chelating agent and a target molecule capable of binding to PSMA is disclosed in International Publication No. 2018 / 215627A1, which is incorporated herein by reference.

[0045] Preferred examples of complexes containing the target molecule and chelating agent include PSMA-617 (shown in formula (3) below), PSMA-I&T (shown in formula (3) below), and Ibu-Dα-PSMA (shown in formula (5) below):

[0046] [ka] [Somatostatin receptor-targeting compounds] Other particularly suitable target molecules bind to somatostatin receptors. Molecules that bind to somatostatin receptors, such as somatostatin analogs, are known in the art. Preferably, the target molecule is a somatostatin receptor-binding peptide. More preferably, the somatostatin receptor-binding peptide is selected from octreotide, octreotate, lanreotide, bapreotide, pasireotide, iratreotide, pentetreotide, depreotide, satreotide, and berdreotide. Even more preferably, the target molecule is a somatostatin receptor-binding peptide selected from octreotide and octreotate.

[0047] In particular, somatostatin receptor (SSTR)-targeted peptides may be used for the treatment of well- and moderately differentiated neuroendocrine neoplasms (NETs). Radioligand therapy is well-established in NETs and can achieve long-term remission and stabilization of tumors in a high proportion of cases. Somatostatin receptor-targeted peptides include, for example, the somatostatin analogs tyr3-octreotide (D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(ol)) and tyr3-octeotrate (D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr) (Capello A et al.: Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177 Luor 90 Y: peptide receptor radionuclide therapy results in vitro, Cancer Biother Radiopharm, October 2003, 18(5):761-8). Further examples of somatostatin receptor antagonists are peptide octreotide (D-Phe-cyclo(Cys-Phe-D-Trp-Lys-Thr-Cys)Thr(ol)) and NOC (D-Phe-cyclo(Cys-1-Nal-D-Trp-Lys-Thr-Cys)Thr(ol)).

[0048] Other examples of compounds that target the somatostatin receptor include somatostatin antagonist peptides such as JR10(p-NO2-Phe-c(D-Cys-Tyr-D-Aph(Cbm)-Lys-Thr-Cys)D-Tyr-NH2); JR11(Cpa-c(D-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys)D-Tyr-NH2); BASS(p-NO2-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)D-Tyr)-NH2; and LM3(p-Cl-Phe-cyclo(D-Cys-Tyr-D-Aph(Cbm)-Lys-Thr-Cys)D-Tyr-NH2).

[0049] A preferred example of a somatostatin analog-based (radio)pharmaceutical is: 177 Lu-DOTATOC( 177 Lu-DOTA-[Tyr3]-Octreotide) 177 Lu-DOTA-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(ol), 177 Lu-DOTANOC( 177 Lu-DOTA-D-Phe-cyclo(Cys-1-Nal-D-Trp-Lys-Thr-Cys)Thr(ol)), 177 Lu-DOTATATE( 177 Lu-DOTA-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Thr-Cys)Tyr), 68 Ga-DOTATOC( 68 Ga-DOTA-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Thr-Cys)Thr(ol)), 68 Ga-DOTANOC( 68 Ga-DOTA-D-Phe-cyclo(Cys-1-Nal-D-Trp-Lys-Thr-Cys)Thr(ol)), 90 Y-DOTATOC( 90 Y-DOTA-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Thr-Cys)Thr(ol)), 90 Y-DOTATATE( 90 Y-DOTA-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Thr-Cys)Thr, 111 In-DTPA Octreotide ( 111 This includes, but is not limited to, in-DTPA-D-Phe-cyclo(Cys-Phe-D-Trp-Lys-Thr-Cys)Thr(ol)).

[0050] Further examples of (radioactive) pharmaceuticals based on somatostatin analogs include: 111 In-DOTA-BASS 111 In-DOTA-p-NO2-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)D-Tyr-NH2, 111 In-DOTA-JR11(111 In-DOTA-Cpa-cyclo[D-Cys-Aph(Hor)-D-Aph(Cbm)-Lys-Thr-Cys]D-Tyr-NH2), 68 Ga-DOTA-JR11(Ga-OPS201)( 68 Ga-DOTA-Cpa-cyclo[D-Cys-Aph(Hor)-D-Aph(Cbm)-Lys-Thr-Cys]D-Tyr-NH2), 68 Ga-DODAGA-JR11(Ga-OPS202)( 68 Ga-NODAGA-Cpa-cyclo[D-Cys-Aph(Hor)-D-Aph(Cbm)-Lys-Thr-Cys]D-Tyr-NH2), 177 Lu-DOTA-JR11(Lu-OPS201)( 177 This includes, but is not limited to, Lu-DOTA-Cpa-cyclo[D-Cys-Aph(Hor)-D-Aph(Cbm)-Lys-Thr-Cys]D-Tyr-NH2).

[0051] Therefore, the target molecule in the radiolabeled complex is preferably a somatostatin receptor target molecule, which can bind to the chelating agent molecule defined above and to the radionuclide defined above, for example 177 It can be complexed with Lu.

[0052] A preferred complex comprising a chelating agent and a target molecule capable of binding to a somatostatin receptor is DOTA-OC([DOTA 0 ,D-Phe 1 ]Octoreotrid), DOTATOC([DOTA 0 ,D-Phe 1 ,Tyr 3 ] Octreotrid; INN: Edtreotid), DOTANOC([DOTA 0 ,D-Phe 1 ,1-Nal 3 ]Octoreotrid), DOTATATE([DOTA 0 ,D-Phe 1 ,Tyr 3] Octreotete; INN: Oxodotreotide), DOTALAN ([DOTA 0 ,D-β-Nal 3 ]Octoreotrid), DOTAVAP([DOTA 0 ,D-Phe 1 ,Tyr 3 This includes bapreotide, satreotide trizoxetane, and satreotide tetraxetane. More preferably, the molecule comprises a chelating agent and a target molecule selected from DOTATOC and DOTATATE.

[0053] Therefore, the radiolabeled complex preferably comprises (i) a radionuclide and (ii) DOTATOC or DOTATATE, or consists thereof. Particularly preferably, the radiolabeled complex (containing a radionuclide, a target molecule and a chelating agent) is 177 Lu-DOTATOC( 177 Lu-edtreotide) or 177 Lu-DOTATATE( 177 It is Lu-oxodotreotide.

[0054] [Folic acid conjugate] Folate receptor (FR)-α has attracted the most attention as a tumor-related target for the targeted therapy concept. In vitro and in vivo targeting of FR-positive tumor cells has been exemplified by numerous research groups using folate conjugates with various therapeutic probes. Therefore, FR has proven to be a valuable target for nuclear imagine using folate radioconjugates.

[0055] A preferred example of a folate conjugate radiopharmaceutical is: 99mTc(Guo et al, J Nucl Med.1999;40:1563-1569;Mathias et al, Bioconjug Chem.2000;11:253-257;Leamon et al, Bioconjug Chem.2002;13:1200-1210;Reddy et al, J Nucl.Med.2004;45:857-866;Muller et al., J Nucl Med Mol Imaging 2006;33:1007-1016;Muller et al., Bioconjug Chem.2006;17:797-806), 111 In (Siegel et al., J Nucl Med. 2003; 44:700-707), 66 / 67 / 68 Ga (Mathias et al., Nucl Med Biol. 1999; 26:23-25; Mathias et al., Nucl Med Biol. 2003; 30:725-731) and 18 Use F (Bettio et al., J Nucl Med. 2006; 47:1153-1160).

[0056] Typical folate conjugates include, for example, 111 In-DTPA-folic acid, 177 Lu-EC0800, 177 Lu-cm09, 149 / 161 Tb-cm09, 99m Tc(CO)3, 99m Tc-EC20, 111 In-DTPA-folic acid, 111 In / 177 Lu-DOTA-Click-Folic Acid, 67 Ga-DOTA-Bz-folic acid ( 67 Ga-EC 800 ), 68 Ga-NODAGA-folate, and the complex shown in formula (6) below:

[0057] [ka] [CCK2 receptor targeting compounds] The CCK2 receptor (cholecystokinin) is located in the central and peripheral nervous systems and is overexpressed in several types of human cancer, including medullary thyroid cancer, small cell lung cancer, and stromal ovarian cancer. Studies have been conducted to develop suitable radioligands for targeting the CCK2 receptor in vivo. Various radiolabeled CCK / gastrin-related peptides have been synthesized and characterized. All peptides commonly possess the C-terminal CCK receptor-binding tetrapeptide sequence Trp-Met-Asp-Phe-NH2, or in their derivatives. Peptides can be classified based on the sequence of their parent peptide (gastrin or CCK) and their morphology (i.e., linear, cyclic, or multimer).

[0058] Examples of CCK receptor ligands include, for example, sargastrinn (Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2), minigastrin 0 (MG-0) D-Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2), and minigastrin 11 (MG-11) D-Glu-Ala-Tyr-Gly-Tr p-Met-Asp-Phe-NH2), Cyclo-minigastrin 1 (Cyclo-MG1) (Cyclo[γ-D-Glu-Ala-Tyr-D-Lys]-Trp-Met-Asp-Phe-NH2), Cyclo-minigastrin 2 (Cyclo-MG2) (Cyclo[γ-D-Glu-Ala-Tyr-D-Lys]-Trp-Nle-Asp-Phe-NH2, Demogastrin 1 (D-Glu-(Glu)5-Ala-Tyr-Gly-Trp- Met-Asp-Phe-NH2), demogastrin 2(D-Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2, H2-Met(His-His-Glu-Ala-Tyr- Gly-Trp-Met-Asp-Phe-NH2), H2-Nle(His-His-Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2), H6-Met(His)6-Glu-Ala- Gastrin analogs such as Tyr-Gly-Trp-Met-Asp-Phe-NH2, and CCK8(D-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2), CCK8(Nle)(D-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH2), sCCK8(D-Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2), sCCK8[Phe 2 (p-CH2SO3H),Nle 3,6 ](D-Asp-Phe(p-CH2SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2), sCCK8[Phe 2 (p-CH2SO3H), HPG 3,6 It is a CCK8 analog such as (D-Asp-Phe(p-CH2SO3H)-HPG-Gly-Trp-HPG-Asp-Phe-NH2).

[0059] CCK receptor-targeting peptides are preferably radiolabeled with radionuclides for imaging or therapeutic applications. Suitable radionuclides include those identified above, and in particular, radionuclides 99m Tc, 111 In, 18 F, 68 Ga, 131 I, 90 Y, and 177 It contains Lu. To enable radiolabeling with radionuclides, a chelating agent bound to a peptide is preferably used. The above-mentioned chelating agents can be used, with DOTA, DOTAGA, DOTAM, DTPA, and HYNIC being preferred.

[0060] Therefore, the radioactive target complex is 177 Lu-DOTA-sargastrine, 111 In-DTPA-MG0, 111 In-DOTA-MG11, 111 In-DOTA-MG 11 (Nle), 111 In-DOTA-H2-Met, 111 In-DOTA-H2-Nle, 111 In-DOTA-H6-Met,[ 99 mTc]2N4,D-Glu 1 -MG( 99m Tc-Demogastrin 1),[ 99m Tc]2N4 0-1 Gly 0 D-Glu 1 -MG( 99m Tc-Demogastrin 2) 99m Tc-HYNIC-MG11, 99m Tc-HYNIC-Cyclo-MG1, 99m CCK2 receptor target molecules such as Tc-HYNIC-cycloMG2; and 111 IN-DTPA-CCK8, 111 In-DTPA-CCK8(Nle), 99m Tc-HYNIC-CCK8, 99m Tc-HYNIC-sCCK8,111 In-DOTA-sCCK8[Phe 2 (p-CH2SO3H), Nle 3、6 ], and 111 In-DOTA-sCCK8[Phe 2 (p-CH2SO3H), HPG 3 , 6 This may include CCK8 analogs such as ].

[0061] [Integrin-binding molecules] Integrins are heterodimeric glycoproteins composed of α- and β-subunits. Twenty-four different combinations of 8 β-units and 18 α-units are known. Integrins mediate cell-cell and cell-matrix interactions, transmitting signals across the cell membrane via in-out and outside-in signaling. Some integrins play crucial roles during tumor-induced angiogenesis and tumor metastasis, as well as during the migration of endothelial cells and tumor cells. Angiogenesis, i.e., the formation of new blood vessels from the existing vascular system, is a critical step in the progression and dissemination of various human tumors. Various therapeutic strategies in oncology focus on inhibiting tumor-induced angiogenesis. Regarding integrins, integrins αVβ3 and αVβ5 have attracted attention due to their prominent role in vascular endothelial cell proliferation. Therefore, one of the most prominent target structures used in the development of radiopharmaceuticals to image angiogenesis is integrin αVβ3.

[0062] Tumor-induced angiogenesis is α v β3 integrin can be blocked in vivo by antagonizing it with a small peptide containing the Arg-Gly-Asp (RGD) amino acid sequence. This tripeptide sequence is naturally present in extracellular matrix proteins, and α v It is the main binding site for β3 integrin. v For the selective expression of β3 integrin, radiolabeled RGD peptide is used in tumors to promote α vIt is an attractive candidate for β3 integrin targeting. Over the past decade, many radiolabeled linear and cyclic RGD peptides have been evaluated as radiotracers for tumor imaging with SPECT or PET and therapeutic agents.

[0063] Suitable radionuclides include the radionuclides identified above, and in particular, radionuclides 18 F, 99m Tc, 68 Ga, 111 In, 131 I, 90 Y, 67 Cu and 177 It contains Lu. To enable radiolabeling with radionuclides, a chelating agent bound to a peptide is preferably used. Suitable chelating agents such as those listed above can be used, with NOTA, DOTA, DOTAGA, DOTAM, DTPA, and HYNIC being preferred.

[0064] For example, 18 F-Galacto-RGD, 99m Tc-NC100692( 99m Tc-malacilatide), 18 F-AH11185( 18 F-Furcyclatide), 18 F-RGD-K5, 68 Ga-NOTA-RGD, 18 F-FPPRGD2, 18 F-AlF-NOTA-PRGD2( 18 F-alphatide), 18 F-NOTA-E[PEG4-c(RGDfk)]2( 18 F-Alphatide II), 68 Ga-NOTA-PRGD2, 67 Cu-cyclam-RAFT-c(-RGDfK-)4, 111 In-DOTA-E-[c(RGDfK)]2, and 99m Tc-HYNIC-E-[c(RGDfK)]2 is included.

[0065] [Neurotensin receptor target compounds] Neurotensin receptor 1 (NTR1) is overexpressed in pancreatic ductal adenocarcinoma, one of the most lethal cancers. Several NTR1 antagonists, such as SR142948A and SR48692, and those developed based on SR142948A have been identified. 177 It is a Lu-labeled DOTA-coupled NTR1 antagonist. 177 Lu-3BP-2273 is under development. NTR1 is used to treat pancreatic ductal adenocarcinoma (Baum RP et al., The Journal of Nuclear Medicine, Vol. 59, No. 5, May 2018).

[0066] Therefore, radiopharmaceuticals may use other radionuclides, such as the above-mentioned radionuclides, and other chelating agents, such as the above-mentioned chelating agents, but the neurotensin receptor 1 is radiolabeled NTR1 antagonists, particularly for the diagnosis or treatment of cancer, preferably 177 Lu- or 68 Ga-labeled NTR1 antagonist, more comfortably, 177 It can be targeted using Lu-3BP-2273.

[0067] [Glucagon-like peptide-1 (GLP-1) receptor target compound] The GLP-1 receptor is overexpressed in virtually all benign insulinomas and gastrinomas. Benign insulinomas, which emerge from pancreatic β-cells and exist as small nodules, secrete insulin that can potentially lead to life-threatening hypoglycemia.

[0068] Therefore, radiopharmaceuticals can target the GLP-1 receptor. A non-limiting example is the 39-mer peptide exendin-4, for example, Lys 40 (Ahx-DOTA- 111 Based on In)NH2-excendin-4 111 In-, 99m Tc-, and 68Examples include Ga-labeled peptides. However, other radionuclides, such as the aforementioned radionuclides, and other chelating agents, such as the aforementioned chelating agents, may be considered.

[0069] [Gastrin-releasing peptide (GRP) receptor-targeting compounds] GRP receptors have been demonstrated in major human tumors such as breast and prostate cancer. Bombecin is a tetradecapeptide neurohormone and an amphibian homolog of mammalian GRP (27-mer peptide). Several bombesin analogs and bombesin antagonists have been developed, using different chelating agents to produce different radioisotopes (e.g., 68 Ga, 64 Cu, 18 It is labeled with F). An example of this is the pan-bombazine analog. 68 Ga-BZH3 (Zhang H et al., Cancer Res 2004;64:6707-6715), and bound to DOTA via a Gly-4-aminobenzoyl spacer. 177 This includes Lu-labeled bombazine (7-14) derivatives (Bodei L et al., Eur J Nucl Med Mol Imaging 2007:34(suppl2):S221).

[0070] [Neurokinin type 1 receptor targeting compounds] Neurokinin type 1 receptors are consistently overexpressed on glioma cells and tumor blood vessels (Hennig IM et al., Int J Cancer 1995;61:786-792). A radiolabeled 11-amino acid peptide substance P (ArgProLysProGlnGlnPhePheGlyLeuMet), which acts via the neurokinin type 1 receptor, can be suitably used to target malignant gliomas. In particular, substance P is conjugated to the chelating agent DOTAGA, 90Y-labeled DOTAGA-substance P has been used in clinical studies (Kneifel S et al, Eur J Nucl Med Mol Imaging. 2007;34:1388-1395). In another study, the feasibility and efficacy of targeted α-radioactive nuclide therapy for brain tumors were evaluated using the α-radioactive conjugate 213Bi-DOTA-[THi8,Met(O2)11]-substance P (Cordier et al, Eur J Nucl Med Mol Imaging. 2010;37:1335-1344).

[0071] Therefore, radiopharmaceuticals can target neurokinin type 1 receptors, particularly as substance P conjugates (containing a radionuclide and a chelating agent that coordinates the radionuclide).

[0072] [Affiliate Link] Affilin is an artificial protein designed to selectively bind to an antigen. Structurally, affilin proteins are derived from either human ubiquitin or γ-B crystallin, respectively. Affilin proteins are constructed by modifying the surface-exposed amino acids of these proteins and isolated by display techniques such as phage display and screening. Affilin proteins are similar to antibodies in terms of affinity and specificity to antigens, but structurally dissimilar, and are a type of antibody mimetic. Affilin® was developed by Scil Proteins GmbH as a potential biopharmaceutical, diagnostic, and affinity ligand. Affilin molecules are readily modifiable and are suitable for the specific elimination of tumor cells by irradiation.

[0073] It is possible to generate multispecific affilin molecules that bind simultaneously to different targets. Radionuclides or cytotoxins can be conjugated to affilin proteins, making them potentially useful for tumor therapy and diagnostics. Radionuclide-chelator-affilin conjugates, for example. 177 Lu-DOTA-affilin is designed for therapeutic purposes.

[0074] Particularly preferred surface molecules are PSMA and somatostatin receptors targeted by the target molecule of the radiolabeled complex. Therefore, the target molecule can preferably bind to PSMA or the somatostatin receptor, for example, as described above.

[0075] The target molecule can be linked to the chelating agent directly or indirectly (for example, by using a linker or spacer). The linking bond is a covalent or non-covalent bond between the target molecule, optionally the linker or spacer, and the chelating agent. Preferably, the bond is a covalent bond. Preferably, the radiolabeled complex includes a linker. Particularly suitable linkers and spacers are described in WO2018 / 215627A1 and WO2020 / 109523A1, which are incorporated herein by reference.

[0076] The target molecule and the chelating agent typically form a complex or molecule (suitable for radiolabeling) together. Various such complexes / molecules are known in the art. Preferred conjugates comprising a chelating agent and a target molecule capable of binding to PSMA are disclosed in International Publication No. 2018 / 215627A1, incorporated herein by reference.

[0077] A preferred conjugate comprising a chelating agent and a target molecule capable of binding to the somatostatin receptor is DOTA-OC([DOTA 0 ,D-Phe 1 ]Octoreotrid), DOTATOC([DOTA 0 ,D-Phe 1 ,Tyr 3 ] Octreotrid; INN: Edtreotid), DOTANOC([DOTA 0 ,D-Phe 1 ,1-Nal 3 ]Octoreotrid), DOTATATE([DOTA 0 ,D-Phe 1 ,Tyr 3] Octreotete; INN: Oxodotreotide), DOTALAN ([DOTA 0 ,D-β-Nal 3 ]Octoreotrid), DOTAVAP([DOTA 0 ,D-Phe 1 ,Tyr 3 This includes bapreotide, satreotide trizoxetane, and satreotide tetraxetane. More preferably, the molecule comprises a chelating agent and a target molecule selected from DOTATOC and DOTATATE.

[0078] Therefore, the radiolabeled complex preferably comprises (i) a radionuclide and (ii) DOTATOC or DOTATATE, or consists thereof. Particularly preferably, the radiolabeled complex (containing a radionuclide, a target molecule and a chelating agent) is 177 Lu-DOTATOC( 177 Lu-edtreotide) or 177 Lu-DOTATATE( 177 It is Lu-oxodotreotide.

[0079] [Stabilizer] To provide stability against radiolysis, a pharmaceutical composition may contain a stabilizer. As used herein, the term “stabilizer” (against radiolysis) refers to an agent that protects an organic molecule against radiolysis. In particular, stabilizers can capture radicals. Radicals can be generated, for example, when a radionuclide emits gamma rays, which break the interatomic bonds of an organic molecule, thereby forming a radical. Stabilizers can thus prevent or reduce radicals from undergoing other chemical reactions. Radicals undergoing other chemical reactions can result in undesirable, potentially ineffective, or even toxic molecules.

[0080] The stabilizer includes ascorbic acid (L-ascorbic acid, vitamin C) and / or its salts (e.g., sodium ascorbate). However, the composition does not contain gentisic acid (2,5-dihydroxybenzoic acid) or its salts. As shown in the attached examples, such formulations not only reduce the complexity of the composition (and its preparation), but surprisingly, also provide higher stability for the radiolabeled complex.

[0081] In some embodiments, other stabilizers besides gentisic acid or its salts may be present in addition to ascorbic acid and / or its salts. Examples of such further stabilizers include methionine, histidine, melatonin, ethanol, and Se-methionine.

[0082] Preferably, the pharmaceutical composition does not contain any further stabilizers in addition to ascorbic acid and / or its salts. Therefore, ascorbic acid and / or its salts are preferably the only stabilizers present in the pharmaceutical composition. In other words, the stabilizers included in the pharmaceutical composition preferably consist of ascorbic acid and / or its salts.

[0083] Various salts of ascorbic acid are known in the art and readily available. Generally, the term “salt” refers to an ionic aggregate of cations and anions composed of a relevant number of cations and anions, and as a result, the product (salt) is electrically neutral (has no net charge). In salts of ascorbic acid, the salt is typically formed with the ascorbate anion. Preferred salts of ascorbic acid include alkali salts of ascorbic acid. The term “alkali salt” refers to a salt that produces hydroxide ions when dissolved in water. Non-limiting examples of preferred salts of ascorbic acid include sodium, potassium, calcium, magnesium, and lithium salts of ascorbic acid; for example, sodium ascorbate, sodium ascorbyl phosphate, potassium ascorbate, calcium ascorbate, magnesium ascorbate, magnesium ascorbyl phosphate, and lithium ascorbate. Most preferably, the salt of ascorbic acid is the sodium salt of ascorbic acid, particularly sodium ascorbate.

[0084] [Composition] The pharmaceutical composition according to the present invention is preferably an aqueous solution, particularly a radiopharmaceutical aqueous solution. As used herein, “aqueous solution” is usually a solution of one or more solutes in water. The pharmaceutical composition may be for intravenous (IV) use / application / administration. The pharmaceutical composition is typically stable, concentrated, and ready for immediate use.

[0085] In some embodiments, the pharmaceutical composition may contain a buffer, such as an acetate buffer, a citrate buffer, or a phosphate buffer. However, the inventors have surprisingly found that ascorbic acid and / or its salts not only provide increased stability to the radiolabeled complex, but also function as a buffer (to maintain a pH suitable for parenteral injection) during (i) radiolabeling of the complex and (ii) during the formulation of the pharmaceutical composition. Therefore, additional buffers are usually not required. Accordingly, it is preferable that the composition does not contain an acetate buffer. It is also preferable that the composition does not contain a citrate buffer. It is also preferable that the composition does not contain a phosphate buffer. More preferably, the pharmaceutical composition does not contain an acetate buffer, a citrate buffer, or a phosphate buffer. Even more preferably, the pharmaceutical composition does not contain any additional buffering agents (in addition to ascorbic acid and / or its salts, which are present as stabilizers and also provide buffering functions).

[0086] In some embodiments, the pharmaceutical composition may contain a metal ion chelating agent such as diethylenetriaminepentaacetic acid (DTPA) or a salt thereof. As used herein, the term “metal ion chelating agent” refers to an agent suitable for complexing radionuclide metal ions, such as DTPA. However, the inventors have found that the addition of a metal ion chelating agent is not necessary. Therefore, the pharmaceutical composition is preferably free of DTPA. More preferably, the pharmaceutical composition is free of a metal ion chelating agent such as DTPA. DTPA is known to induce side effects such as nausea, vomiting, diarrhea, chills, fever, itching, muscle spasms, headache, dizziness, and chest pain.

[0087] In some embodiments, the pharmaceutical composition does not contain a physiological (saline) solution, particularly a 0.9% NaCl solution (saline). In some embodiments, the pharmaceutical composition does not contain NaCl.

[0088] It is even more preferable that the only excipient contained in the pharmaceutical composition (i.e., a component of the pharmaceutical composition that is not the active ingredient, e.g., a radiolabeled complex) is ascorbic acid and / or a salt thereof; as well as water (e.g., (sterile) water for injection and / or highly purified water). Therefore, the pharmaceutical composition preferably consists (essentially) of the following:

[0089] (a) Radiolabeled complexes, and optionally one or more precursors thereof; (b) Ascorbic acid and / or its salts; and (c) water Preferably, (as described above) the pharmaceutical composition comprises both ascorbic acid and its salts. Therefore, it is particularly preferable that the pharmaceutical composition comprises ascorbic acid and sodium ascorbate (preferably without the further stabilizers described above).

[0090] The weight ratio of ascorbic acid salt to ascorbic acid in the pharmaceutical composition, particularly the weight ratio (w / w) of sodium ascorbate to ascorbic acid, is preferably 30:1 to 70:1, more preferably 36:1 to 66:1, even more preferably 40:1 to 60:1, even more preferably 45:1 to 55:1, and particularly preferably 45:1 to 50:1. Therefore, the amount (weight) of ascorbic acid salt (particularly sodium ascorbate) is preferably considerably greater than the amount (weight) of ascorbic acid, as described above.

[0091] Therefore, in particular, when both ascorbic acid and its salts (especially sodium ascorbate) are present in the pharmaceutical composition, the concentration of ascorbic acid in the composition is preferably considerably lower than the concentration of the salts of ascorbic acid (especially sodium ascorbate).

[0092] Preferably, the concentration of ascorbic acid in the pharmaceutical composition is in the range of 0.5 to 5.0 mg / ml, preferably in the range of 0.7 to 3.0 mg / ml, more preferably in the range of 0.8 to 2.0 mg / ml, even more preferably in the range of 0.9 to 1.5 mg / ml, and even more preferably in the range of 1.0 to 1.25 mg / ml. For example, the concentration of ascorbic acid in the pharmaceutical composition may be about 1.11 mg / ml.

[0093] Regarding the concentration of ascorbic acid salts, the concentration of ascorbate, particularly sodium ascorbate, in the pharmaceutical composition is preferably in the range of 10 mg / ml to 100 mg / ml, preferably in the range of 20 mg / ml to 90 mg / ml, more preferably in the range of 30 mg / ml to 80 mg / ml, even more preferably in the range of 40 mg / ml to 70 mg / ml, even more preferably in the range of 44 mg / ml to 66 mg / ml, and particularly preferably in the range of 50 mg / ml to 60 mg / ml. For example, the concentration of ascorbic acid salt, particularly sodium ascorbate, in the pharmaceutical composition may be about 51 mg / ml.

[0094] In some embodiments, the pharmaceutical composition is substantially ethanol-free. Higher concentrations of ethanol may be associated with tolerability issues, and as a result, ethanol may be limited or avoided. In some embodiments, the amount of ethanol in the pharmaceutical composition is 5% or less, preferably 2% or less, and more preferably 1% or less in the final pharmaceutical composition (to be injected / injected). Even more preferably, the solution is ethanol-free.

[0095] In some embodiments, the pharmaceutical composition consists of (essentially) the following:

[0096] (a) 177 Lu-DOTATOC (and one or more precursors thereof); (b) 40 mg / ml to 70 mg / ml of sodium ascorbate and 1.0 to 1.25 mg / ml of ascorbic acid, with a weight ratio (w / w) of sodium ascorbate to ascorbic acid in the range of 40:1 to 60:1; and (c) water In some embodiments, the pharmaceutical composition is a precursor of a radiolabeled complex, particularly, 177 It is substantially free of Lu-DOTATOC precursors. In some embodiments, the radiolabeled complex in the pharmaceutical composition is particularly, 177 The amount of Lu-DOTATOC precursor in the final pharmaceutical composition (to be injected / injected) is, in particular, the amount of the radiolabeled complex. 177 The amount of Lu-DOTATOC is 5% or less, preferably 2% or less, more preferably 1% or less, and even more preferably 0.5% or less. Even more preferably, the pharmaceutical composition is a precursor of the radiolabeled complex, in particular, 177 It does not contain the precursor of Lu-DOTATOC.

[0097] As shown in the attached examples, the pharmaceutical composition according to the present invention can provide a shelf life of at least 96 hours, especially when stored at 40°C or below (e.g., 40°C / 70%RH (relative humidity)). In some embodiments, the shelf life of the pharmaceutical composition is at least 24 hours, preferably at least 48 hours, more preferably at least 72 hours, and even more preferably at least 96 hours, especially when stored at 40°C or below. In some embodiments, the shelf life of the pharmaceutical composition is 24 to 168 hours, preferably 48 to 168 hours, more preferably 72 to 168 hours, and even more preferably 96 to 168 hours, especially when stored at 40°C or below.

[0098] The use of the specific stabilizers described herein ensures high chemical stability of at least 95%, 96%, 97%, 98%, 99%, or 100% with respect to the chemical purity of the radiolabeled complex, even after 96 hours.

[0099] Furthermore, the use of the specific stabilizers described herein ensures high stability, at least 95% radiochemical stability, for radionuclide complexes of radiochemical purity. For example, the various formulations described herein have at least 95% radiochemical purity. 177Lu-DOTATOC was found after 96 hours, particularly when stored at temperatures below 40°C. More preferably, the radiochemical purity of the pharmaceutical composition can be maintained at ≥96%, more preferably ≥96.5%, and even more preferably ≥97% for at least 96 hours, particularly when stored at 40°C. For this purpose, radiochemical purity can be determined by HPLC known in the art, for example, using reverse-phase chromatography (e.g., column: Acclaim120, C18, 3 μm, 3 × 150 mm) under gradient conditions with UV and radiochemical detection.

[0100] The pharmaceutical composition according to the present invention may be provided as a single-dose product, for example, in a vial containing a single dose of a radiolabeled complex. For this purpose, the vial may contain about 10 to 25 ml of the pharmaceutical composition, preferably 15 to 20 ml, more preferably 16 to 19 ml, and even more preferably about 18 ml. The single dose can deliver 7.5 GBq ± 10% of radioactivity upon injection.

[0101] Preferably, each of the one or more stabilizers present in the (final) pharmaceutical composition is already present during complex formation (radiation labeling).

[0102] As used herein, the expression “present during complex formation” is intended to refer to such agents / compounds present in the reaction mixture for complex formation (radiolabeling) (also called the “radiolabeled composition”). To obtain the radiolabeled reaction mixture (radiolabeled composition), a radionuclide solution is added to a solution containing a chelating agent linked to a target molecule (or vice versa). Thus, any agents / compounds present during complex formation (radiolabeling), such as stabilizers, may be present in the radionuclide solution, in the solution containing the chelating agent linked to the target molecule, or in a separate solution to which they are added. After obtaining the radiolabeled composition, high temperature may be applied to the radiolabeled composition (containing the agents / compounds) for a specified time to promote complex formation (radiolabeling).

[0103] As described above, it is preferable that each of the one or more stabilizers present in the (final) pharmaceutical composition is already present during complex formation (radiation labeling). However, the concentration and / or weight ratio of the stabilizers in the radiation-labeled composition (reaction mixture) during complex formation (radiation labeling) is preferably different from the concentration and / or weight ratio of the stabilizers in the (final) pharmaceutical composition. For example, one or more stabilizers present during complex formation (radiation labeling) may be added after complex formation (radiation labeling).

[0104] As used herein, the expression "after complex formation (radiographic labeling)" refers to the time when the complex formation (radiographic labeling) reaction is complete. For example, if high temperature is applied for radiolabeling, "after complex formation (radiographic labeling)" may refer to the time when the radiolabeled composition (radiographic labeling reaction mixture) is no longer exposed to high temperature (e.g., when the radiolabeled composition is cooled to ambient temperature again). In particular, "after complex formation (radiographic labeling)" may refer to the formulation of the (final) pharmaceutical composition, for example, by diluting the radiolabeled mixture with water.

[0105] Therefore, it is preferable that ascorbic acid and / or its salts are present during complex formation (radiation labeling). It is also preferable that ascorbic acid and / or its salts are added after complex formation (radiation labeling). More preferably, ascorbic acid and / or its salts are present during complex formation (radiation labeling), and ascorbic acid and / or its salts are added after complex formation (radiation labeling).

[0106] More preferably, ascorbic acid and its salts, particularly sodium ascorbate, are present during complex formation (radiation labeling). Therefore, it is preferable that ascorbic acid and its salts, particularly sodium ascorbate, are present during complex formation (i.e., in the radiation-labeled composition) in a weight ratio of about 2:1 to 6:1, preferably about 3:1 to 5:1, more preferably about 3.5:1 to 4.5:1, even more preferably about 3.75:1 to 4.25:1, and even more preferably about 4:1 (sodium ascorbate:ascorbic acid).

[0107] Preferably, ascorbic acid is present during complex formation (i.e., in the radiolabeled composition) at a concentration of 1 to 50 mg / ml, preferably 5 to 40 mg / ml, more preferably 7 to 30 mg / ml, even more preferably 10 to 20 mg / ml, even more preferably 10 to 15 mg / ml, for example, about 13.3 mg / ml.

[0108] Salts of ascorbic acid, particularly sodium ascorbate, are also preferably present during complex formation (i.e., in the radiolabeled composition) at a concentration of 10 to 100 mg / ml, preferably 20 to 80 mg / ml, more preferably 30 to 70 mg / ml, even more preferably 45 to 60 mg / ml, and even more preferably 50 to 55 mg / ml, for example, about 53.3 mg / ml.

[0109] Preferably, a salt of ascorbic acid, particularly sodium ascorbate (preferably not ascorbic acid), is added after complex formation (during the formulation of the pharmaceutical composition).

[0110] More preferably, ascorbic acid and its salts, particularly sodium ascorbate, are present during complex formation (radiation labeling); and salts of ascorbic acid, particularly sodium ascorbate (preferably not ascorbic acid), are added after complex formation (during the formulation of the pharmaceutical composition).

[0111] It is also preferable that ascorbic acid and / or its salts, particularly sodium ascorbate, are the only stabilizers present during complex formation (radioactive labeling) and after complex formation (e.g., during formulation of the pharmaceutical composition).

[0112] Particularly preferably, the excipients of the pharmaceutical composition consist of sodium ascorbate, ascorbic acid, and water (e.g., sterile water for injection and / or highly purified water). Therefore, the pharmaceutical composition preferably consists of (essentially) the following:

[0113] (a) Radiolabeled complexes, and optionally one or more precursors thereof; (b) Ascorbic acid and sodium ascorbate; and (c) Water (e.g., sterile water for injection and / or highly purified water).

[0114] The concentration of ascorbic acid in this pharmaceutical composition is preferably in the range of 0.9 to 1.5 mg / ml, more preferably in the range of 1.0 to 1.25 mg / ml. For example, the concentration of ascorbic acid in the pharmaceutical composition may be 1.11 mg / ml ± 1.1 mg / ml. The concentration of sodium ascorbate in this pharmaceutical composition is preferably in the range of 40 mg / ml to 70 mg / ml, more preferably in the range of 50 mg / ml to 60 mg / ml. For example, the concentration of sodium ascorbate in the pharmaceutical composition may be 51 mg / ml ± 5.1 mg / ml. Furthermore, in this pharmaceutical composition, the radionuclide is 177 Preferably, the chelating agent is Lu, the target molecule is a peptide that binds to PSMA or a somatostatin receptor. The radionuclide may be present at a concentration that provides a volume radioactivity of 0.42 GBq / ml ± 0.04 GBq / ml.

[0115] [Medical treatment and use] In a further embodiment, the present invention also provides the use of the above-described pharmaceutical compositions in pharmaceuticals. For example, the above-described pharmaceutical compositions may preferably be used in the treatment or (in vitro) diagnosis of cancer (for example, by using isolated samples, e.g., blood samples or tumor tissue). Accordingly, the present invention also provides a method for treating cancer or initiating, enhancing or prolonging an antitumor response in a subject requiring the above-described pharmaceutical composition, the method comprising administering the above-described pharmaceutical composition to the subject.

[0116] For medical purposes, the pharmaceutical composition is generally understood to contain an effective amount of the radiolabeled complex. As used herein, “effective amount” means an amount of drug sufficient to enable the diagnosis of a disease to be treated and / or to significantly induce a positive change. However, at the same time, the “effective amount” may be small enough to avoid serious side effects, i.e., small enough to allow a reasonable relationship between benefits and risks. The “effective amount” may vary depending on the specific condition being diagnosed or treated, as well as the age and physical condition of the patient being treated, the severity of the condition, the duration of treatment, the nature of any accompanying treatments, the specific pharmaceutically acceptable excipients or carriers used, and similar factors. Thus, the “effective amount” may be determined by a physician on an ad-hoc basis in a particular situation. Generally, the effective dose can be determined by routine experiments, for example, by using animal models. Such models include, but are not limited to, rabbit, sheep, mouse, rat, dog, and non-human primate models. The therapeutic efficacy and toxicity of radiolabeled complexes can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, by determining the LD50 (lethal dose for 50% of the population) and ED50 (therapeutably effective dose for 50% of the population). The dose ratio between the toxic effect and the therapeutic effect is the therapeutic index and can be expressed as the ratio LD50 / ED50. Data obtained from cell culture assays and animal studies can be used when determining the dose range for use in humans. The dose of the conjugate is preferably within the range of circulating concentrations that include an ED50 with little to no toxicity.

[0117] As used herein, the terms “diagnosis” or “diagnosing” refer to the act of identifying a disease based on its signs and symptoms, and / or, in this case, the analysis of biological markers (such as genes or proteins) that indicate the disease.

[0118] As used herein, the terms “treatment” or “treating” a disease include preventing or defending against the disease (i.e., preventing the progression of clinical symptoms); inhibiting the disease (i.e., stopping or suppressing the progression of clinical symptoms); and / or mitigating the disease (i.e., causing regression of clinical symptoms). As should be understood, since the final inducing event may be unknown or potential, it is not always possible to distinguish between “preventing” and “suppressing” a disease or disorder. Therefore, the term “prevention” is understood to constitute a type of “treatment” that encompasses both “prevention” and “suppression.” Thus, the term “treatment” includes “prevention.” Therefore, the term “treatment” includes both preventive treatment (before the onset of the disease) and therapeutic treatment (after the onset of the disease).

[0119] The pharmaceutical compositions described herein are typically administered parenterally. Administration may be systemic, for example, by intravenous (iv), subcutaneous, intramuscular, or intradermal injection. Alternatively, administration may be local, for example, by intratumoral injection. The pharmaceutical compositions described above may be administered to subjects requiring them several times a day, daily, every other day, weekly, or monthly.

[0120] The pharmaceutical compositions of the present invention, in particular, those comprising a radiolabeled complex having a target molecule that binds to PSMA, can be used for the treatment or diagnosis of any cancer expressing PSMA. In particular, the presence of PSMA-expressing cells or tissues may indicate prostate tumors (cells), metastatic prostate tumors (cells), renal tumors (cells), pancreatic tumors (cells), bladder tumors (cells), and combinations thereof. Therefore, the cancers are preferably prostate cancer, pancreatic cancer, renal cancer, or bladder cancer.

[0121] The pharmaceutical compositions of the present invention, in particular, those comprising a radiolabeled complex having a target molecule that binds to the somatostatin receptor, can be used for the treatment or diagnosis of any cancer expressing the somatostatin receptor. Therefore, the cancer is preferably a neuroendocrine tumor (NET). In particular, NETs may be selected from the group consisting of gastrointestinal and pancreatic neuroendocrine tumors, carcinoid tumors, accessory neuroendocrine tumors, paragangliomas, medullary thyroid carcinomas, pulmonary neuroendocrine tumors, thymic neuroendocrine tumors, carcinoid tumors or pancreatic neuroendocrine tumors, pituitary adenomas, adrenal carcinomas, Merkel cell carcinomas, breast cancers, non-Hodgkin lymphomas, Hodgkin lymphomas, tumors of the head and neck, neuroepithelial carcinoma (bladder), renal cell carcinoma, hepatocellular carcinoma, GISTs, neuroblastomas, cholangiocarcinomas, cervical tumors, Ewing's sarcoma, osteosarcoma, small cell lung cancer (SCLC), prostate cancer, melanomas, meningiomas, gliomas, medulloblastomas, hemangioblastomas, undifferentiated neuroectodermal tumors, neuroectodermal tumors, and nasal neuroblastomas. Further non-limiting examples of NET tumors include functional carcinoid tumors, insulinomas, gastrinomas, vasoactive intestinal peptidocarcinomas (VIPs), glucagonomas, serotoninomas, histaminomas, ACTHomas, pheochromocytomas, and somatostatinomas.

[0122] The aforementioned pharmaceutical compositions may be used for both imaging and therapeutic purposes, i.e., as “theragnostic” agents. As used herein, the term “theragnostic” includes applications to “therapeutic only,” “diagnostic only,” and “therapeutic and diagnostic.” Accordingly, in a further embodiment, the present invention also provides a method for detecting the presence of cancer cells and / or tissue (in vitro), comprising (a) contacting the cancer cells and / or tissue with the pharmaceutical composition of the present invention, and (b) applying detection means, optionally radiographic imaging, to detect the cells and / or tissue.

[0123] In in vivo and in vitro use and methods, radioimaging can be achieved using any means and methods known in the Art. Preferably, radioimaging may include positron emission tomography (PET) or single-photon emission computed tomography (SPECT). Target cells or tissues detected by radioimaging of the complex of the present invention may preferably include (optionally malignant) prostate cells or tissue, (optionally malignant) spleen cells or tissue, or (optionally malignant) kidney cells or tissue.

[0124] [Preparation process for pharmaceutical compositions] In a further embodiment, the present invention also provides a method for producing the pharmaceutical composition according to the present invention described above, comprising the following steps: (i) Formation of the radiolabeled complex described above; and (ii) Formulation of the pharmaceutical composition described above.

[0125] It is understood that the above detailed description applies to the process for preparing the pharmaceutical composition according to the present invention. For example, the detailed embodiments described above for the radiolabeled complex are applied accordingly to the process for preparing the pharmaceutical composition according to the present invention. Similarly, the detailed embodiments described above for the formulation of the pharmaceutical composition are applied accordingly to the process for preparing the pharmaceutical composition according to the present invention. As another example, the embodiments described above for the radiolabeled composition (reaction mixture) are also applied accordingly to the process for preparing the pharmaceutical composition according to the present invention.

[0126] Therefore, step (i), i.e., the formation of the radiolabeled complex, is preferably carried out in a radiolabeled composition comprising (or essentially consisting of) the following: (a) The target molecule linked to the radionuclide and the chelating agent described above; and (b) A radiolabeling buffer comprising (or consisting of) water and ascorbic acid and / or a salt thereof.

[0127] In step (i), the radiolabeled reaction mixture (radiolabeled composition) is obtained by adding the radionuclide solution to a solution containing the chelating agent linked to the target molecule (or vice versa). Furthermore, the radiolabeled composition may contain further components, such as stabilizers, which may be contained in the radionuclide solution, the solution containing the chelating agent linked to the target molecule, or any other solution to which it is added.

[0128] Furthermore, as described above, the radiolabeled composition preferably comprises a radiolabeled buffer which may (or may consist of) water and ascorbic acid and / or its salts, such as sodium ascorbate. Preferably, the radiolabeled composition in step (i) has a pH of about 4.0 to 5.5, more preferably about 4.5 to 5.0. The buffer is useful in maintaining such a favorable pH range.

[0129] After obtaining the radiolabeled composition, a high temperature can be applied to the radiolabeled composition (containing the drug / compound) for a specified time, particularly to facilitate complex formation (radiolabeling). For example, temperatures in the range of 60 to 120°C, preferably 70 to 110°C, more preferably 80 to 100°C, and particularly 87 ± 4°C can be applied to the radiolabeled composition in step (i). Therefore, step (i) is carried out at a temperature of 87 ± 4°C, particularly preferably. The high temperature can be applied for a specified time such as 10 to 40 minutes, preferably 15 to 35 minutes, and more preferably 20 to 30 minutes, and in particular, the high temperature can be applied for 25 ± 3 minutes.

[0130] Preferably, in this method, and especially in step (i), the radionuclides used to form the radiolabeled complex are as described above (with their respective detailed / preferred embodiments). In particular, the radionuclides are 177 It may be Lu. For this purpose, for example, lutetium for radiolabeling, which provides 40 ± 4 GBq / ml in 0.04 M hydrochloric acid. 177 Lu (Lu) Chloride solution, etc. 177LuCl3 can be used as the radionuclide solution in step (i). In the radiolabeled composition obtained in step (i), the radionuclide is present at a concentration that provides a volume radioactivity of preferably 2 to 20 GBq / mL, preferably 3 to 16 GBq / mL, more preferably 2 to 10 GBq / mL, even more preferably 4 to 12 GBq / mL, and even more preferably 6.0 to 9.5 GBq / mL. In some embodiments, the radionuclide is provided from day 1 to day 4 of the activity reference time (ART). In particular, the radionuclide is provided with an initial activity of 6.0 to 9.5 GBq / mL, for example, 8 to 11.5 GBq per 1.1 to 1.2 mL (from day 1 to day 4 of the activity reference time (ART)).

[0131] Preferably, in this method, particularly in step (i), the target molecule linked to the chelating agent used to form the radiolabeled complex is as described above (in each detailed / preferred embodiment). In particular, the target molecule linked to the chelating agent may be DOTATOC. In the radiolabeled composition obtained in step (i), the target molecule linked to the chelating agent is preferably presented at a concentration of 50-150 μg / ml, preferably 60-140 μg / ml, more preferably 70-130 μg / ml, and even more preferably 80-120 μg / ml, and even more preferably the target molecule linked to the chelating agent is present in the radiolabeled composition at a concentration of 100 ± 10 μg / ml.

[0132] As described above, ascorbic acid and / or its salts, such as sodium ascorbate, are preferably present in step (i) (in the radiolabeled composition). More preferably, both ascorbic acid and its salts, and especially sodium ascorbate, are preferably present in step (i) (in the radiolabeled composition). In particular, ascorbic acid and its salts, especially sodium ascorbate, can form a radiolabeled buffer. As described above, the radiolabeled buffer is useful for maintaining the pH of the radiolabeled composition in step (i) preferably in the range of about pH 4.0 to 5.5, more preferably about pH 4.5 to 5.0. The use of the radiolabeled buffer in step (i) allows for the addition of various amounts of lutetium as needed while the pH is maintained. 177 Even though a lutetium (Lu) chloride solution can be used for radioactive labeling, it has the advantage of being able to maintain pH. Therefore, to obtain the expected pH for each specific case, lutetium ( 177 It is not necessary to calculate a specific amount of base depending on a specific amount of Lu) chloride solution. More preferably, ascorbic acid and its salts, particularly sodium ascorbate, are present in step (i) in a weight ratio of about 2:1 to 6:1, preferably about 3:1 to 5:1, more preferably about 3.5:1 to 4.5:1, even more preferably about 3.75:1 to 4.25:1, and even more preferably about 4:1 (sodium ascorbate:ascorbic acid) (in the radiolabeled composition, particularly by forming the radiolabeled buffer).

[0133] As described above, ascorbic acid is preferably present during step (i) at a concentration of 1 to 50 mg / ml, preferably 5 to 40 mg / ml, more preferably 7 to 30 mg / ml, even more preferably 10 to 20 mg / ml, even more preferably 10 to 15 mg / ml, for example, about 13.3 mg / ml (in the radiolabeled composition, in particular for forming the radiolabeled buffer).

[0134] It is also preferable that a salt of ascorbic acid, particularly sodium ascorbate, be present during step (i) (in the radiolabeled composition) at a concentration of 10 to 100 mg / ml, preferably 20 to 80 mg / ml, more preferably 30 to 70 mg / ml, more preferably 40 to 65 mg / ml, even more preferably 45 to 60 mg / ml, and even more preferably 50 to 60 or 50 to 55 mg / ml, for example, about 53.3 mg / ml.

[0135] In step (ii), the (final) pharmaceutical composition is formulated, for example, by diluting the radiolabeled mixture with water or another diluent (such as physiological saline). Thereafter, further components of the (final) pharmaceutical composition, such as one or more stabilizers and / or buffers, can be added. In this way, the final volume (and concentration) of the pharmaceutical composition can be achieved, for example, as a ready-to-use pharmaceutical composition, for example, as a single-dose product. For this purpose, a final volume of about 10 to 25 ml, preferably 15 to 20 ml, more preferably 16 to 19 ml, and even more preferably about 18 ml of the pharmaceutical composition can be achieved by appropriate dilution (and optionally the addition of further components).

[0136] Step (ii) follows (directly or indirectly) step (i), that is, step (ii) is performed after complex formation (radiation labeling). In step (ii), the radiation-labeled composition is not normally exposed to high temperatures anymore (for example, by cooling the radiation-labeled composition when it reaches ambient temperature again).

[0137] Preferably, in step (ii), an aqueous solution of ascorbic acid and / or its salts, particularly sodium ascorbate, is added to the radiolabeled composition (reaction mixture) obtained in step (i). In other words, ascorbic acid and / or its salts, such as sodium ascorbate, is preferably added in step (ii) (to the radiolabeled composition obtained in step (i)) to formulate the (final) pharmaceutical composition. In particular, it is preferable that ascorbic acid and / or its salts are present in step (i) and further added in step (ii).

[0138] More preferably, in order to formulate the (final) pharmaceutical composition, a salt of the above-mentioned ascorbic acid, particularly sodium ascorbate (without ascorbic acid), is added in step (ii) (to the radiolabeled composition obtained in step (i)). Therefore, it is preferable that ascorbic acid and its salts, particularly sodium ascorbate, are present during step (i), and that a salt of (preferably the same) ascorbic acid, particularly sodium ascorbate (without ascorbic acid), is added during step (ii).

[0139] In particular, in step (ii), an aqueous solution of a salt of ascorbic acid, especially sodium ascorbate (without ascorbic acid), is preferably added to the radiolabeled composition (reaction mixture) obtained in step (i). Preferably, the concentration of the salt of ascorbic acid, especially sodium ascorbate, in the solution added in step (ii) is in the range of 10 to 100 mg / ml, preferably 20 to 80 mg / ml, more preferably 30 to 70 mg / ml, even more preferably 40 to 60 mg / ml, and even more preferably 45 to 55 mg / ml, particularly about 50 mg / ml.

[0140] It is also preferable that ascorbic acid and / or its salts are the only stabilizers present throughout the entire process, particularly in the radiolabeled composition of step (i) and in the (final) pharmaceutical composition of step (ii). In other words, preferably, other stabilizers (other than ascorbic acid and / or its salts, particularly sodium ascorbate) are not used throughout the entire process, i.e., in the radiolabeled composition of step (i) and in the (final) pharmaceutical composition of step (ii), and other stabilizers (other than ascorbic acid and / or its salts, particularly sodium ascorbate) are not present. Even more preferably, ascorbic acid and / or sodium ascorbate are the only stabilizers present throughout the entire process, particularly in the radiolabeled composition of step (i) and in the (final) pharmaceutical composition of step (ii). In other words, preferably, no other stabilizers (other than ascorbic acid and / or sodium ascorbate) are used throughout the process, i.e., the radiolabeled composition of step (i) and the (final) pharmaceutical composition of step (ii) do not contain any other stabilizers (other than ascorbic acid and / or sodium ascorbate).

[0141] The present invention also provides pharmaceutical compositions obtained by the above-described treatment of the present invention. Such pharmaceutical compositions typically exhibit the characteristics of the above-described pharmaceutical compositions. The inventors have found that the pharmaceutical compositions obtained as described herein have excellent stability. Furthermore, the inventors have found that the addition of metal ion chelating agents such as DTPA is not required in the pharmaceutical compositions obtained as described herein.

[0142] [Brief explanation of the drawing] A brief description of the attached drawings is given below. The drawings are intended to illustrate the present invention in more detail. However, they are not intended to limit the subject matter of the present invention in any way.

[0143] [Figure 1] For Example 3, the chromatograms and results obtained for the composition according to the present invention (A) and the control composition according to the prior art (B) at the end of synthesis (EOS) are shown.

[0144] [Figure 2] For Example 3, the chromatograms of the composition according to the present invention (A) and the control composition according to the prior art (B), obtained 72 hours after the end of synthesis (EOS), are shown.

[0145] [Figure 3] For Example 3, the chromatograms and results for the composition according to the present invention (A) and the comparative composition according to the prior art (B), obtained 96 hours after the end of synthesis (EOS), are shown.

[0146] [Examples] Specific examples illustrating various embodiments and aspects of the present invention are presented below. However, the present invention is not limited in scope by the specific embodiments described herein. The following preparations and examples are given to enable those skilled in the art to better understand and implement the present invention. However, the present invention is not limited in scope by the illustrated embodiments, which are intended only as illustrative examples of a single aspect of the present invention, and functionally equivalent methods are within the scope of the present invention. In fact, in addition to those described herein, various modifications of the present invention will be readily apparent to those skilled in the art from the foregoing description, the accompanying drawings, and the following examples. All such modifications fall within the scope of the appended claims.

[0147] [Example 1:[ 177 [Effects of various buffer systems on the radiolabeling yield of Lu]Lu-DOTATOC] [ 177 Regarding the yield of radiolabeling of Lu]Lu-DOTATOC, various buffer systems of different types and concentrations were investigated in the radiolabeling reaction. For this purpose, the chemical precursor DOTATOC was dissolved in various test buffers, and the radionuclide precursor dissolved in 0.04 M hydrochloric acid was also investigated. 177 It was added directly to a vial containing LuCl3. The reaction mixture was heated at 80-95°C for 15-30 minutes, [ 177 Lu]Lu-DOTATOC was obtained.

[0148] The tested buffer systems and results are shown in Table 1 below:

[0149] [Table 1] The results shown in Table 1 indicate that the buffer (LH045) containing gentisic acid but not ascorbic acid or its salts yielded the least desirable result, with a purity of only 96.1%. In contrast, all compositions containing ascorbic acid or its salts but not gentisic acid yielded a purity of at least 97.5%, among others, the exemplary buffer LH045. 055 LD-160429-C yielded a purity of at least 97.5%, demonstrating the best results.

[0150] [Example 2:[ 177 [Protective effects of various formulations related to the autoradiolysis of Lu]Lu-DOTATOC] next,[ 177 The protective effect of Lu]Lu-DOTATOC against autoradiolysis was tested in various formulations and concentrations. For this purpose, [ 177 The reaction mixture from Example 1 containing Lu]Lu-DOTATOC was diluted with various formulation solutions, passed through a 0.22 μm filter, and placed in a sterile vial sealed with a septum. 177 Lu]Lu-DOTATOC was stored in an overhead location at 40°C and 70% relative humidity in a controlled atmosphere chamber.

[0151] The tested formulations and results are shown in Table 2 below ("WFI" = "Sterile water for injection"):

[0152] [Table 2] The results shown in Table 2 indicate that when 0.9% NaCl (physiological saline) is used without a stabilizer, considerable radiolysis is observed after 24 to 70 hours. For example, if the composition is "CF 025When gentisic acid is included, as in "-B", radiolysis is still considerable, especially after 48 hours. In contrast, when the composition contains ascorbic acid or a salt thereof but does not contain gentisic acid, a strong protective effect against radiolysis was observed, especially at 70 or 96 hours.

[0153] [Example 3: Comparison of the formulation of the present invention with the formulation of prior art] Next, the protective effect of the composition of the present invention was compared with a prior art formulation, namely the formulation described in US10,596,278B2. US10,596,278B2 describes a formulation that maintains a radiochemical purity (RCP) of 95% or more for at least 72 hours when stored at 25°C.

[0154] For this purpose, the present invention is described below. 177 A Lu-DOTATOC composition was prepared. For a single dose, the amount of peptide (DOTATOC acetate GMP precursor) was fixed at 150 μg, 7.5 ± 0.7 GBq, in ART. This corresponds to 11.3 ± 1.1 GBq at the time of preparation, for a 96-hour storage life. The reaction buffer contained 80 ± 8 mg of sodium ascorbate and 20 ± 2 mg of ascorbic acid in 0.04 N hydrochloric acid. 177 The volume of LuCl3 ranged from 200 to 800 μL. As a result, the labeled mixture was in the range of 1.2 to 1.8 mL in a 2 mL acid-washed glass vial. Labeling was carried out at 87 ± 4°C for 25 minutes. The reaction mixture was then formulated with 50 mg / mL sodium ascorbate to a final volume of 18 mL. Detailed volumes and activities at the time of use are shown in Table 3 below:

[0155] [Table 3] Furthermore, the contrast 177The Lu-DOTATOC composition was prepared as described in U.S. Patent No. 10,596,278 B2. Specifically, for a single dose, the peptide (DOTATOC acetate GMP precursor) content was fixed at 250 μg, 7.4 ± 0.7 GBq by ART. This corresponds to 9.3 ± 0.9 GBq at the time of preparation, which lasts for 72 hours of storage. The reaction buffer contained 11.43 μL of acetate, 16.5 mg of gentisic acid, and 16.5 mg of sodium acetate. The total reaction volume was 550 μL. Labeling was carried out at 91.5°C for 15 minutes. The reaction mixture was then formulated with 70 mg of ascorbic acid, 1.25 mg of DTPA, 171.3 mg of NaCl, and 16 mg of NaOH, and all were diluted with ultrapure water to a final volume of 25 mL. Detailed volumes and activities at the time of use are shown in Table 4 below:

[0156] [Table 4] After formulation, the resulting composition was stored at 40°C (and room temperature) for at least 96 hours.

[0157] The obtained formulations were subjected to quality control at (1) end of synthesis (EOS), (2) 72 hours after EOS, and (3) 96 hours after EOS. Quality control was performed to determine the assay, chemical purity, radiochemical purity, and identity of [Lu-177]-edotreotide (DOTATOC) in the [Lu-177]-DOTATOC drug. This was done using reverse-phase chromatography (column: Acclaim120, C18, 3 μm, 3 × 150 mm) under gradient conditions with UV and radiochemical detection. For quality control, the sample was diluted with 0.1 M HCl to achieve a radioactivity concentration (RAC) of 130 MBq / mL at the time of measurement. A blank run was performed before sample injection to confirm the absence of contamination.

[0158] The results are shown in Table 5 below. "Sample 1" is the present invention described above. 177 "Sample 2" refers to the Lu-DOTATOC composition, while "Sample 2" is a control prepared as described in U.S. Patent No. 10,596,278B2.177 This refers to the Lu-DOTATOC composition.

[0159] [Table 5] Further data and chromatograms for composition (A) according to the present invention and a control composition (B) according to the prior art are shown in Figure 1 (at EOS), Figure 2 (72 hours after EOS), and Figure 3 (96 hours after EOS).

[0160] These results demonstrate the beneficial effects of the formulation according to the present invention compared to the prior art. In particular, radiolysis is strongly reduced and product stability is maintained even 96 hours after EOS. The formulation according to the present invention contains only very small amounts of impurities, which are still within the specification of less than 1.0% for each individual impurity. In contrast, the prior art formulation (US10,596,278B2) can only maintain stability up to 72 hours after EOS. In particular, radiolysis is clearly enhanced in the control formulation, which can be seen, for example, at 1.51% impurity at 72 hours after EOS and a relative retention time (RRT) of 0.92. [Brief explanation of the drawing]

[0161] A brief description of the attached drawings is given below. The drawings are intended to illustrate the present invention in more detail. However, they are not intended to limit the subject matter of the present invention in any way.

[0162] [Figure 1] For Example 3, the chromatograms and results obtained for the composition according to the present invention (A) and the control composition according to the prior art (B) at the end of synthesis (EOS) are shown.

[0163] [Figure 2] For Example 3, the chromatograms of the composition according to the present invention (A) and the control composition according to the prior art (B), obtained 72 hours after the end of synthesis (EOS), are shown.

[0164] [Figure 3] For Example 3, the chromatograms and results for the composition according to the present invention (A) and the comparative composition according to the prior art (B), obtained 96 hours after the end of synthesis (EOS), are shown.

Claims

1. (a) a radiolabeled complex comprising (i) a radionuclide and (ii) a targeting molecule linked to a chelator; and (b) a stabilizer against radiation degradation comprising ascorbic acid and / or its salts; 13. A pharmaceutical composition comprising the formula:

2. (i) the radionuclide is 177 Lu (lutetium-177), and / or (ii) the chelating agent is DOTA, and / or (iii) the targeting molecule binds to a PSMA or somatostatin receptor.

3. 3. The pharmaceutical composition of claim 1 or 2, wherein the radiolabeled complex comprises or consists of (i) the radionuclide and (ii) DOTATOC or DOTATATE.

4. The pharmaceutical composition of claim 1 or 2, wherein the composition is an aqueous solution.

5. 3. The pharmaceutical composition of claim 1 or 2, wherein the stabilizer comprises ascorbic acid and / or its salts.

6. 3. The pharmaceutical composition of claim 1 or 2, wherein the composition does not contain an additional buffer, such as an acetate buffer.

7. The composition, (a) said radiolabeled complex, and optionally one or more precursors thereof; (b) ascorbic acid and / or its salts; and (c) water 3. The pharmaceutical composition of claim 1 or 2, consisting essentially of:

8. 3. The pharmaceutical composition of claim 1 or 2, wherein the stabilizer comprises ascorbic acid and its salts.

9. 3. The pharmaceutical composition of claim 1, wherein the salt of ascorbic acid is sodium ascorbate.

10. 3. The pharmaceutical composition of claim 1 or 2, wherein the composition comprises ascorbic acid and sodium ascorbate.

11. and / or the weight ratio of sodium ascorbate:ascorbic acid is from 30:1 to 70:1, or from 40:1 to 60:1, or from 45:1 to 55:1, or from 45:1 to 50:1; and / or and / or the concentration of ascorbic acid in the composition is in the range of 0.5-5.0 mg / ml, or 0.7-3.0 mg / ml, or 0.8-2.0 mg / ml, or 0.9-1.5 mg / ml, or 1.0-1.25 mg / ml; and / or 9. The pharmaceutical composition according to claim 8, wherein the concentration of ascorbate, in particular sodium ascorbate, in the composition is in the range of 10 mg / ml to 100 mg / ml, or 20 mg / ml to 90 mg / ml, or 30 mg / ml to 80 mg / ml, or 40 mg / ml to 70 mg / ml, or 50 mg / ml to 60 mg / ml.

12. 3. The pharmaceutical composition of claim 1 or 2, which is substantially free of ethanol.

13. the composition has a shelf life of at least 96 hours; and / or The radiochemical purity of the composition is maintained at 97% or greater for at least 96 hours; and / or A single dose allows the delivery of 7.5 GBq ± 10% of radioactivity upon injection; and / or The pharmaceutical composition of claim 1 or 2, wherein the composition is provided in a volume of 15 to 20 ml.

14. Ascorbic acid and / or its salts are present during complex formation (radiolabeling) and ascorbic acid and / or its salts are added after complex formation (radiolabeling), and / or Ascorbic acid and its salts, in particular sodium ascorbate, are present during complex formation (radiolabeling), and salts of ascorbic acid, in particular sodium ascorbate, are added after complex formation (during formulation of the pharmaceutical composition), and / or 3. The pharmaceutical composition according to claim 1 or 2, wherein ascorbic acid and / or its salts are the only stabilizers present during complex formation (radiolabeling) and thereafter (during formulation of the pharmaceutical composition).

15. 3. The pharmaceutical composition according to claim 1 or 2, wherein ascorbic acid and its salts, in particular sodium ascorbate, are present in the complex formation (radiolabeling) in a weight ratio (sodium ascorbate:ascorbic acid) of about 2:1 to 6:1, or about 3:1 to 5:1, or about 3.5:1 to 4.5:1, or about 3.75:1 to 4.25:1, or about 4:

1.

16. Ascorbic acid is present in the complex (radiolabel) at a concentration of 1-50 mg / ml, or 5-40 mg / ml, or 7-30 mg / ml, or 10-20 mg / ml, or 10-15 mg / ml; and / or 3. The pharmaceutical composition according to claim 1 or 2, wherein the salt of ascorbic acid, in particular sodium ascorbate, is present in the complex formation (radiolabeling) in a concentration of 10-100 mg / ml, or 20-80 mg / ml, or 30-70 mg / ml, or 45-60 mg / ml, or 50-55 mg / ml.

17. 3. The pharmaceutical composition of claim 1, wherein the excipients of the pharmaceutical composition consist essentially of sodium ascorbate, ascorbic acid, and water.

18. 18. The pharmaceutical composition of claim 17, wherein the concentration of sodium ascorbate is 51 mg / ml ± 5.1 mg / ml and the concentration of ascorbic acid is about 1.11 mg / ml ± 1.1 mg / ml.

19. The radionuclide 177 3. The pharmaceutical composition of claim 1 or 2, wherein the chelating agent is DOTA and the targeting molecule is PSMA or a peptide that binds to a somatostatin receptor.

20. 20. The pharmaceutical composition of claim 19, wherein the radionuclide is present in a concentration providing a volumetric activity of 0.42 GBq / ml ± 0.04 GBq / ml.

21. A pharmaceutical composition according to claim 1 or 2 for use in medicine.

22. 3. A pharmaceutical composition according to claim 1 or 2 for use in the treatment of cancer.

23. A method for preparing the pharmaceutical composition according to claim 1 or 2, comprising the steps of: (i) formation of a radiolabeled complex according to claim 1 or 2 (radiolabeling); and (ii) Formulation of a pharmaceutical composition according to claim 1 or 2.

24. 24. The method of claim 23, wherein step (i) is carried out in a radiolabeling composition comprising: (a) the targeting molecule linked to the radionuclide and the chelator; and (b) A radiolabeling buffer comprising water and ascorbic acid and / or a salt thereof.

25. The radionuclide 177 Lu, for example 177 LuCl 3 24. The method of claim 23, wherein:

26. 25. The method of claim 24, wherein the radionuclide is present in the radiolabeled composition at a concentration providing a volumetric activity of 6.0 to 9.5 GBq / mL.

27. 25. The method of claim 24, wherein the targeting molecule linked to the chelating agent is defined in claim 2.

28. 28. The method of claim 27, wherein the targeting molecule linked to the chelator is present in the radiolabeled composition at a concentration of 100±10 μg / ml.

29. Ascorbic acid and / or its salts are present in step (i) and further added in step (ii); and / or 24. The method according to claim 23, wherein ascorbic acid and its salts, in particular sodium ascorbate, are present in step (i) and a salt of ascorbic acid, in particular sodium ascorbate, is added in step (ii).

30. 24. The method of claim 23, wherein ascorbic acid and / or its salts are the only stabilizers present during the entire process.

31. ascorbic acid and its salts, in particular sodium ascorbate, are present in step (i) in a weight ratio (sodium ascorbate:ascorbic acid) of about 2:1 to 6:1, or about 3:1 to 5:1, or about 3.5:1 to 4.5:1, or about 3.75:1 to 4.25:1, or about 4:1; and / or ascorbic acid is present in step (i) at a concentration of 1 to 50 mg / ml, or 5 to 40 mg / ml, or 7 to 30 mg / ml, or 10 to 20 mg / ml, or 10 to 15 mg / ml; and / or 24. The method according to claim 23, wherein the salt of ascorbic acid, in particular sodium ascorbate, is present in step (i) in a concentration of from 10 to 100 mg / ml, or from 20 to 80 mg / ml, or from 30 to 70 mg / ml, or from 45 to 60 mg / ml, or from 50 to 55 mg / ml.

32. the radiolabeled composition in step (i) has a pH of about 4.0 to 5.5, or about 4.5 to 5.0; and / or Step (i) is carried out at a temperature of 87±4° C.; and / or 25. The method of claim 24, wherein step (i) is carried out for 25±3 minutes.

33. In step (ii), an aqueous solution of ascorbic acid and / or its salts is added to the radiolabeled composition obtained in step (i), or In step (ii), an aqueous solution of an ascorbate salt, in particular sodium ascorbate, is added to the radiolabeled composition obtained in step (i), 25. The method according to claim 24, wherein the concentration of the ascorbate, in particular sodium ascorbate, in the solution added in step (ii) is in the range of 10 to 100 mg / ml, or 20 to 80 mg / ml, or 30 to 70 mg / ml, or 40 to 60 mg / ml, or 45 to 55 mg / ml.

34. A pharmaceutical composition obtainable by the method of claim 23.